Demographics | | | | | | |
Age*, years | | 72 (61 to 77) | | 74 (62 to 78) | | 71 (56 to 78) |
<70 years | | 15 (44%) | | 8 (47%) | | 7 (41%) |
⩾70 years | | 19 (56%) | | 9 (53%) | | 10 (59%) |
Male | | 17 (50%) | | 7 (41%) | | 10 (59%) |
White | | 32 (94%) | | 17 (100%) | | 15 (88%) |
BMI† (kg/m2) mean (SD) | | 26 (3) | | 26 (4) | | 26 (3) |
Test treatment initiation | | | | | | |
Onset to treatment* | | 3.6 (2.8 to 5.0) | | 3.6 (2.6 to 4.9) | | 3.6 (2.8 to 5.0) |
<4 hours | | 19 (56%) | | 10 (59%) | | 9 (53%) |
⩾4 hours | | 15 (44%) | | 7 (41%) | | 8 (47%) |
Pre-stroke disability | | | | | | |
BI* | | 100 (100 to 100) | | 100 (100 to 100) | | 100 (100 to 100) |
MRS* | | 0 (0 to 1) | | 0 (0 to 1) | | 0 (0 to 1) |
Stroke severity and subtype | | | | | | |
Baseline NIHSS score* | | 13 (11 to 18) | | 13 (11 to 18) | | 13 (10 to 19) |
4–9 | | 6 (17.6%) | | 3 (17.6%) | | 3 (17.6%) |
10–20 | | 23 (67.6%) | | 12 (70.6%) | | 11 (64.7%) |
⩾21 | | 5 (14.7%) | | 2 (11.8%) | | 3 (17.6%) |
Ischaemic | | 29 (85.3%) | | 17 (100%) | | 12 (70.6%) |
OCSP classification | | | | | | |
TACS | | 15 (44.1%) | | 10 (58.8%) | | 5 (29.4%) |
PACS | | 9 (26.5%) | | 4 (23.5%) | | 5 (29.4%) |
LACS | | 4 (11.8%) | | 2 (11.8%) | | 2 (11.8%) |
POCS | | 1 (2.9%) | | 1 (5.9%) | | 0 (0%) |
Haemorrhagic | | | | | | |
PICH | | 5 (14.7%) | | 0 (0%) | | 5 (29.4%) |
Risk factors | | | | | | |
Atrial fibrillation | | 6 (17.6%) | | 3 (17.6%) | | 3 (17.6%) |
Hypertension | | 18 (52.9%) | | 9 (52.9%) | | 9 (52.9%) |
Diabetes mellitus | | 2 (5.9%) | | 0 (0%) | | 2 (11.8%) |
Current smoker | | 12 (35.3%) | | 7 (41.2%) | | 5 (29.4%) |
Ex-smoker | | 6 (17.6%) | | 2 (11.8%) | | 4 (23.5%) |
Total cholesterol* (mmol/l) | | 5.4 (4.6 to 6.1) | | 5.4 (4.9 to 6.1) | | 5.2 (4.6 to 6.0) |
Previous stroke/TIA | | 6 (17.6%) | | 4 (23.5%) | | 2 (11.8%) |
Ischaemic heart disease | | 9 (26.5%) | | 4 (23.5%) | | 5 (29.4%) |